Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial

Elizabeth N Allen, Francesca Little, Tunisio Camba, Yasmin Cassam, Jaishree Raman, Andrew Boulle, Karen I Barnes, Elizabeth N Allen, Francesca Little, Tunisio Camba, Yasmin Cassam, Jaishree Raman, Andrew Boulle, Karen I Barnes

Abstract

Background: An artemisinin-based combination therapy, artesunate (AS) plus sulphadoxine-pyrimethamine (SP), was compared to SP monotherapy to provide evidence of further treatment options in southern Mozambique.

Methods: Between 2003 and 2005, 411 patients over one year and 10 kg with uncomplicated Plasmodium falciparum malaria were randomly allocated SP (25/1.25 mg per kg day 0) or AS/SP (as above plus 4 mg/kg artesunate days 0, 1 and 2). Allocation was concealed, but treatment was open-label except to microscopists. The primary objective was the relative risk of treatment failure, which was assessed using World Health Organization response definitions modified to a 42-day follow-up.

Results: Of the 411 subjects enrolled, 359 (87.3%) completed the follow up period (SP n = 175, AS/SP n = 184). A survival analysis including 408 subjects showed that the polymerase chain reaction-adjusted cure rates were 90.4% (95% confidence interval [CI] 84.9%-93.9%) and 98.0% (95% CI 94.8%-99.3%) for SP and AS/SP respectively. Multivariable analysis showed that treatment with AS/SP decreased the relative hazard of treatment failure by 80% compared to SP (hazard ratio [HR] 0.2; 95% CI 0.1-0.6) and age over seven years decreased the relative hazard of failure by 70% (HR 0.3; 95% CI 0.1-0.9), when compared to younger age. However, having a quintuple dhfr/dhps mutation increased the relative hazard of failure compared to fewer mutations (HR 3.2; 95% CI 1.3-7.5) and baseline axillary temperature increased the relative hazard of failure by 50% for each degree C increase (HR 1.5; 95% CI 1.1-2.2).

Conclusion: While both treatments were efficacious, AS plus SP significantly decreased the relative hazard of treatment failure compared to SP monotherapy Artesunate plus sulphadoxine-pyrimethamine, but not sulphadoxine-pyrimethamine monotherapy, met the current WHO criteria of >95% efficacy for policy implementation.

Trial registration: NCT00203736 and NCT00203814.

Figures

Figure 1
Figure 1
Geographical location of the 4 study sites in Maputo Province showing prevalence of malaria at the study start.
Figure 2
Figure 2
Subject disposition and the analysis dataset.
Figure 3
Figure 3
Kaplan-Meier survival curves for time to treatment failure.
Figure 4
Figure 4
Kaplan-Meier survival curves for time to parasite clearance.

References

    1. World Health Organization, Regional Office for Africa. Country health system fact sheet 2006 Mozambique
    1. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001;184:770–76. doi: 10.1086/322858.
    1. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Minireview. Antimicrob Agents Chemother. 1997;41:1413–22.
    1. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347:1654–8. doi: 10.1016/S0140-6736(96)91488-9.
    1. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181–92.
    1. von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebech C, Gosling R. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet. 2000;355:352–57. doi: 10.1016/S0140-6736(99)10237-X.
    1. World Health Organization: Guidelines for the treatment of malaria
    1. International Artemisinin Study Group Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9–17. doi: 10.1016/S0140-6736(03)15162-8.
    1. WorldWide Antimalarial Resistance Network (WARN)
    1. Raman J, Sharp B, Kleinschmidt I, Roper C, Streat E, Kelly V, Barnes KI. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am J Trop Med Hyg . 2008;78:256–261.
    1. Sharp BL, Kleinschmidt I, Streat E, Maharaj R, Barnes KI, Durrheim DN. Seven years of regional malaria control collaboration-Mozambique, South Africa and Swaziland. Am J Trop Med Hyg . 2007;76:42–47.
    1. Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJD, Watkins WM. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg. 2005;73:166–70.
    1. World Health Organization Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:62.
    1. World Health Organization Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission WHO/MAU961077. 1996.
    1. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria
    1. World Health Organization . Basic malaria microscopy Part 1 Learner's Guide. Switzerland: Macmillan/Presses Centrales; 1991.
    1. Wooden J, Keyes S, Sibley CH. PCR and strain identification in Plasmodium falciparum. Parasitol Today. 1993:303–5. doi: 10.1016/0169-4758(93)90131-X.
    1. Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, Schmidt-Ott JR, Lehman LG, Walliker D, Kremsner PG. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg . 1997;91:719–724. doi: 10.1016/S0035-9203(97)90539-3.
    1. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590–6. doi: 10.1086/514159.
    1. Collett D. Modelling survival data in medical research. 2. Chapman and Hall/CRC. Press LLC; 2003.
    1. Department of Health . Guidelines for good practice in the conduct of clinical trails in South Africa. Department of Health, Pretoria, South Africa; 2000.
    1. Haviid L. Naturally acquired immunity to Plasmodium falciparum malaria in Africa. Acta Trop Acta Trop. 2005;95:270–275. doi: 10.1016/j.actatropica.2005.06.012.
    1. Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, Tanner M, Alonso PL. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med . 2007;4:e242. doi: 10.1371/journal.pmed.0040242.
    1. Dorsey G, Kamya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira ET, Rosenthal PJ. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg. 2000;62:686–692.
    1. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80:582–596. doi: 10.1016/j.clpt.2006.08.016.
    1. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol . 2008;24:127–134.
    1. Terlouw DJ, Courval JM, Kolczak MS, Rosenberg OS, Oloo AJ, Kager PA, Lal AA, Nahlen BL, ter Kuile FO. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. J Infect Dis. 2003;187:467–76. doi: 10.1086/367705.
    1. Govere JM, la Grange JJ, Durrheim DN, Freese JA, Sharp BL, Mabuza A, Mngomezulu N, Bredenkamp BL. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. Trans R Soc Trop Med Hyg. 1999;93:644. doi: 10.1016/S0035-9203(99)90082-2.
    1. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590–6. doi: 10.1086/514159.
    1. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–8. doi: 10.1086/338566.
    1. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6:121. doi: 10.1186/1475-2875-6-121.
    1. Hamer DH, MacLeod WB, Addo-Yobo E, Duggan CP, Estrella B, Fawzi WW, Konde-Lule JK, Mwanakasale V, Premji ZG, Sempértegui F, Ssengooba FP, Yeboah-Antwi K, Simon JL. Age, temperature, and parasitaemia predict chloroquine treatment failure and anaemia in children with uncomplicated Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2003;97:422–8. doi: 10.1016/S0035-9203(03)90076-9.
    1. Fontanet AL, Walker AM. Predictors of treatment failure in multiple drug resistant falciparum malaria: results from a 42-day follow-up of 224 patients in Eastern Thailand. Am J Trop Med Hyg. 1993;49:465–72.
    1. Luxemburger C, Nosten F, Raimond SD, Chongsuphajaisiddhi T, White NJ. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg. 1995;53:522–525.
    1. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, Barnes K, Myint HY, Adjuik M, Olliaro P, Pukrittayakamee S, Looareesuwan S, Hien TT, Farrar J, Nosten F, Day NP, White NJ. In vivo assessment of drug efficacy against plasmodium falciparum malaria: duration of follow-up. Agents Chemother. 2004;48:4271–4280. doi: 10.1128/AAC.48.11.4271-4280.2004.
    1. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, Kamwendo DD, Tadesse E, Chaluluka E, Meshnick SR. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother. 2005;49:3919–3921. doi: 10.1128/AAC.49.9.3919-3921.2005.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅